SIGLEC15 and breast carcinoma: In breast cancer, SIGLEC15 is overexpressed in both tumor cells and tumor-infiltrating immune cells, where its expression is correlated with advanced disease stage, lymph node metastasis, and unfavorable clinical outcomes.21